A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects

• Drug: PF-06648671
  Experimental Pfizer compound which will be dosed as oral suspension
• Drug: Placebo
  Placebo which will be given as oral suspension

• Experimental: Single Ascending Doses Cohort 1
  subjects receive 3 active doses and one placebo
  Interventions:

  • Drug: PF-06648671
  • Drug: Placebo
• Experimental: Single Ascending Doses Cohort 2
  subjects receive 3 doses and one placebo
  Interventions:

  • Drug: PF-06648671
  • Drug: Placebo
• Experimental: Cohort 3
  optional cohort
  Interventions:

  • Drug: PF-06648671
  • Drug: Placebo

Inclusion Criteria:

• Healthy male and/or female subjects of non childbearing potential
• BMI of 17.5 to 30.5 kg/m2 and a total body weight >50 kg (110 lbs)
• Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drg allergies, but excluding untreated asymptomatic, seasonal allergies at the time of dosing);
• Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study medication (whichever is longer)
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the subject inappropriate for entry into this study.